Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Merck's experimental injectable remigromig held its own against the current gold standard for diabetic macular edema (DME) in a 52-week trial. The drug works via a novel mechanism — activating the Wnt pathway to repair leaky retinal blood vessels — potentially the first new approach for retinal vascular disease in over 20 years. Some safety signals around retinal vascular complications are still under review.
Merck's experimental drug remigromig has cleared a major clinical hurdle, matching the effectiveness of Roche's ranibizumab — the current standard of care — in treating diabetic macular edema (DME). In a 52-week trial of 984 patients, remigromig was non-inferior to ranibizumab in improving best-corrected visual acuity, a key measure of vision sharpness.
What makes remigromig stand out is its mechanism: rather than blocking blood vessel growth like existing anti-VEGF therapies, it activates the Wnt pathway to help repair the retina's leaky blood-vessel barrier and reduce swelling. Analysts called it potentially the first novel mechanism of action for retinal vascular diseases in more than two decades — a significant milestone if it reaches approval.
That said, the drug isn't in the clear yet. Merck flagged a higher rate of discontinuation due to retinal vascular complications compared to ranibizumab, and analysts say full safety data are needed before assessing its commercial viability. Full results will be presented at the American Academy of Ophthalmology annual meeting next month.
By the Numbers:
Why it matters: DME is a leading cause of vision loss in people with diabetes, and current treatments — while effective — require frequent injections and don't work for everyone. A drug with a genuinely new mechanism could expand treatment options for millions of patients globally, making remigromig a closely watched pipeline asset.
